Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F14%3A33152523" target="_blank" >RIV/61989592:15310/14:33152523 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61389030:_____/14:00429983 RIV/00209805:_____/14:#0000508

Výsledek na webu

<a href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0089228" target="_blank" >http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0089228</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1371/journal.pone.0089228" target="_blank" >10.1371/journal.pone.0089228</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy

Popis výsledku v původním jazyce

CDKs are key regulators of the cell cycle and RNA polymerase II mediated transcription. Several pharmacol. CDK inhibitors are currently in clinical trials as potential cancer therapeutics and some of them also exhibit antiviral effects. Olomoucine II androscovitine, purine-based inhibitors of CDKs, were described as effective antiviral agents that inhibit replication of a broad range of wild type human viruses. Olomoucine II and roscovitine show high selectivity for CDK7 and CDK9, with important functions in the regulation of RNA polymerase II transcription. RNA polymerase II is necessary for viral transcription and following replication in cells. We analyzed the effect of inhibition of CDKs by olomoucine II on gene expression from viral promoters andcompared its effect to widely-used roscovitine. We found that both roscovitine and olomoucine II blocked the phosphorylation of RNA polymerase II C-terminal domain. However the repression of genes regulated by viral promoters was strongl

Název v anglickém jazyce

Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy

Popis výsledku anglicky

CDKs are key regulators of the cell cycle and RNA polymerase II mediated transcription. Several pharmacol. CDK inhibitors are currently in clinical trials as potential cancer therapeutics and some of them also exhibit antiviral effects. Olomoucine II androscovitine, purine-based inhibitors of CDKs, were described as effective antiviral agents that inhibit replication of a broad range of wild type human viruses. Olomoucine II and roscovitine show high selectivity for CDK7 and CDK9, with important functions in the regulation of RNA polymerase II transcription. RNA polymerase II is necessary for viral transcription and following replication in cells. We analyzed the effect of inhibition of CDKs by olomoucine II on gene expression from viral promoters andcompared its effect to widely-used roscovitine. We found that both roscovitine and olomoucine II blocked the phosphorylation of RNA polymerase II C-terminal domain. However the repression of genes regulated by viral promoters was strongl

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

PLoS One

ISSN

1932-6203

e-ISSN

—

Svazek periodika

9

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

"e89228"

Kód UT WoS článku

000331717900066

EID výsledku v databázi Scopus

—